Timothy Hayes
Addiction Psychiatry Santa Monica, CA Medical Doctor
NPI 1194722264 CMS profile 596342
1301 20Th St, Ste 210, Santa Monica, CA 90404
General payments
$125
Research payments
$0
Ownership & investment interest
$0
Through program year 2019, Timothy Hayes of Santa Monica, CA is reported in the CMS Open Payments database as having received $125 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 33rd percentile of Addiction Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2019 | General | $125 | 1 |
Beside peers
- Timothy Hayes
- Addiction Psychiatry median
- Middle half of Addiction Psychiatry
- National median
In program year 2025, general payments to Timothy Hayes were reported at $0. Among 180 Addiction Psychiatry profiles paid that year, the median was $138 and the middle half received between $45 and $421.
Show as a table
| Year | Timothy Hayes | Addiction Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $125 | $142 | $56–$476 | $163 |
| 2020 | $0 | $78 | $21–$210 | $114 |
| 2021 | $0 | $112 | $35–$458 | $132 |
| 2022 | $0 | $113 | $39–$343 | $149 |
| 2023 | $0 | $134 | $47–$429 | $160 |
| 2024 | $0 | $129 | $42–$349 | $164 |
| 2025 | $0 | $138 | $45–$421 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
228
Drug cost
$7,148
Branded share of claims
16.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Modafinil | Generic | 25 | $1,567 | |
| Quetiapine Fumarate | Generic | 31 | $1,556 | |
| Bupropion Xl Bupropion Hcl | Brand | 38 | $1,478 | |
| Escitalopram Oxalate | Generic | 60 | $1,287 | |
| Duloxetine Hcl | Generic | 23 | $568 | |
| Eszopiclone | Generic | 11 | $254 | |
| Lamotrigine | Generic | 25 | $250 | |
| Sertraline Hcl | Generic | 15 | $188 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Addiction Psychiatry in California
Robert Anthenelli
Addiction Psychiatry · San Diego, CA
Ariel Gavino
Addiction Psychiatry · Anaheim, CA
Sean Barlow
Addiction Psychiatry · Palm Desert, CA
Edward Moore
Addiction Psychiatry · Beverly Hills, CA
Frank Tan
Addiction Psychiatry · Los Angeles, CA
Juan Pequeno
Addiction Psychiatry · Needles, CA
Related records
Addiction Psychiatry in California
Practitioners in the same specialty and state, ranked by reported value.
All Addiction Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.